亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

医学 杜瓦卢马布 多西紫杉醇 化疗 临床终点 顺铂 围手术期 内科学 肺癌 外科 肿瘤科 癌症 阶段(地层学) 泌尿科 新辅助治疗 临床试验 免疫疗法 乳腺癌 无容量 古生物学 生物
作者
Sacha I. Rothschild,Alfred Zippelius,E.I. Eboulet,Spasenija Savic Prince,Daniel Betticher,Adrienne Bettini,Martin Früh,Markus Joerger,Didier Lardinois,Hans Gelpke,Laetitia Mauti,Christian Britschgi,Walter Weder,Solange Peters,Michael Mark,Richard Cathomas,Adrian F. Ochsenbein,Wolf-Dieter Janthur,Christine Waibel,Nicolas Mach
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (26): 2872-2880 被引量:341
标识
DOI:10.1200/jco.21.00276
摘要

PURPOSE: For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in the SAKK 16/00 trial and is an accepted standard of care. We investigated the additional benefit of perioperative treatment with durvalumab. METHODS: once every 3 weeks followed by two doses of durvalumab 750 mg once every 2 weeks. Durvalumab was continued for 1 year after surgery. The primary end point was 1-year EFS. The hypothesis for statistical considerations was an improvement of 1-year EFS from 48% to 65%. RESULTS: Sixty-eight patients were enrolled, 67 were included in the full analysis set. Radiographic response rate was 43% (95% CI, 31 to 56) after neoadjuvant chemotherapy and 58% (95% CI, 45 to 71) after sequential neoadjuvant immunotherapy. Fifty-five patients were resected, of which 34 (62%) achieved a major pathologic response (MPR; ≤ 10% viable tumor cells) and 10 (18%) among them a complete pathologic response. Postoperative nodal downstaging (ypN0-1) was observed in 37 patients (67%). Fifty-one (93%) resected patients had an R0 resection. There was no significant effect of pretreatment PD-L1 expression on MPR or nodal downstaging. The 1-year EFS rate was 73% (two-sided 90% CI, 63 to 82). Median EFS and overall survival were not reached after 28.6 months of median follow-up. Fifty-nine (88%) patients had an adverse event grade ≥ 3 including two fatal adverse events that were judged not to be treatment-related. CONCLUSION: The addition of perioperative durvalumab to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer is safe and exceeds historical data of chemotherapy alone with a high MPR and an encouraging 1-year EFS rate of 73%.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
6秒前
追寻从寒发布了新的文献求助10
9秒前
11秒前
ding的应助被超级小飞侠采纳,获得10
11秒前
12秒前
12秒前
火星仙人掌完成签到 ,获得积分10
13秒前
隐形期待完成签到,获得积分10
14秒前
yinian完成签到,获得积分10
17秒前
终梦的应助被zhang采纳,获得10
17秒前
17秒前
爱静静完成签到,获得积分0
18秒前
19秒前
streetlight发布了新的文献求助10
22秒前
yinian发布了新的文献求助10
23秒前
GQ完成签到 ,获得积分10
23秒前
Ava的应助被ping采纳,获得10
23秒前
在水一方的应助被追寻从寒采纳,获得10
29秒前
y'y'y发布了新的文献求助10
30秒前
30秒前
专注的思松完成签到,获得积分10
33秒前
ABJ完成签到 ,获得积分10
34秒前
洛久竹完成签到 ,获得积分10
36秒前
37秒前
科研通AI6.2的应助被吐司采纳,获得10
38秒前
xx2026发布了新的文献求助10
43秒前
寒冷的凌萱完成签到,获得积分10
44秒前
46秒前
Sp1dey完成签到 ,获得积分10
46秒前
fantasy的应助被xby0328采纳,获得10
47秒前
FIGGIEKIO发布了新的文献求助10
50秒前
翻翻书完成签到,获得积分10
50秒前
碎片发布了新的文献求助10
51秒前
心随以动完成签到 ,获得积分10
53秒前
渡安完成签到 ,获得积分10
53秒前
多情莫言完成签到,获得积分10
54秒前
修辛完成签到 ,获得积分10
58秒前
zzz完成签到,获得积分10
58秒前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541